KIOTI Provides Customers with Additional Ways to Save

May 13, 2020

KIOTI Tractor has launched a variety of sales and finance programs through May 31, 2020 to provide savings to customers affected by the current economic situation. These include deferred payments, increased financing options and extending KIOTI’s Heroes Reward Program to include frontline medical workers.

While our communities navigate these uncertain times, we want to be sure our customers know these savings options are available to them. Details on the programs and links to more information are included below:

The KIOTI Heroes Reward Program has been extended to include frontline medical workers. This extension applies in both the United States and Canada.

The KIOTI Confidence Protection Promise is available until the end of May. With the purchase of any KIOTI tractor in both the United States and Canada, qualifying customers have no payments for the first 90 days.

Zero percent financing for 84 months on CS, CX and CK models, with no money down. This deal is available in both the United States and Canada, and it can be combined with the 90-day payment deferral.

Zero percent financing for 96 months with 10 percent down on CS models in Canada. This deal can be combined with the 90-day payment deferral.

Source : KIOTI

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.